Five-year clinical outcomes of the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer
Authors:
Open Access
- 14 May 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (19) , e25765
Abstract
This study evaluated the 5-year clinical outcomes of the Genoss DES, the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer. We previously conducted the first-in-patient prospective, multicenter, randomized trial with a 1:1 ratio of patients using the Genoss DES and Promus Element stents; the angiographic and clinical outcomes of the Genoss DES stent were comparable to those of the Promus Element stent. The primary endpoint was major adverse cardiac events (MACE), which was a composite of death, myocardial infarction (MI), and target lesion revascularization (TLR) at 5 years. We enrolled 38 patients in the Genoss DES group and 39 in the Promus Element group. Thirty-eight patients (100%) from the Genoss DES group and 38 (97.4%) from the Promus Element group were followed up at 5 years. The rates of MACE (5.3% vs 12.8%, P = .431), death (5.3% vs 10.3%, P = .675), TLR (2.6% vs 2.6%, P = 1.000), and target vessel revascularization (TVR) (7.9% vs 2.6%, P = .358) at 5 years did not differ significantly between the groups. No TLR or target vessel revascularization was reported from years 1 to 5 after the index procedure, and no MI or stent thrombosis occurred in either group during 5 years. The biodegradable polymer Genoss DES and durable polymer Promus Element stents showed comparable low rates of MACE at the 5-year clinical follow-up.Keywords
This publication has 24 references indexed in Scilit:
- Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery DiseaseJACC: Cardiovascular Interventions, 2013
- Coronary stents: historical development, current status and future directionsBritish Medical Bulletin, 2013
- Stent Thrombosis in SwedenCirculation: Cardiovascular Interventions, 2009
- Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting StentsJACC, 2008
- Thrombosis and Drug-Eluting StentsJACC, 2007
- Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary StentsNew England Journal of Medicine, 2007
- Drug-Eluting Stent and Coronary ThrombosisCirculation, 2007
- Pathology of Drug-Eluting Stents in HumansJACC, 2006
- Hypersensitivity Cases Associated With Drug-Eluting Coronary StentsJACC, 2006
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003